Zimmer Biomet (NYSE:ZBH) Issues FY 2026 Earnings Guidance

Zimmer Biomet (NYSE:ZBH) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 8.470-8.590 for the period, compared to the consensus estimate of 8.480. The company issued revenue guidance of $8.6 billion-$8.6 billion, compared to the consensus revenue estimate of $8.5 billion.

Analyst Upgrades and Downgrades

ZBH has been the topic of a number of research analyst reports. Truist Financial reiterated a “hold” rating and set a $92.00 price objective (down from $98.00) on shares of Zimmer Biomet in a research note on Wednesday, April 29th. Sanford C. Bernstein upped their price target on Zimmer Biomet from $91.00 to $93.00 and gave the company a “market perform” rating in a report on Thursday. BMO Capital Markets reiterated a “market perform” rating and set a $96.00 price objective on shares of Zimmer Biomet in a research report on Thursday. Canaccord Genuity Group set a $83.00 target price on Zimmer Biomet in a report on Wednesday, April 29th. Finally, Citizens Jmp dropped their price target on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a research note on Wednesday, April 29th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $103.30.

Zimmer Biomet Stock Down 1.6%

ZBH traded down $1.54 on Thursday, reaching $96.62. 1,205,835 shares of the company traded hands, compared to its average volume of 2,325,955. The stock’s 50 day moving average price is $89.61 and its 200-day moving average price is $90.02. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95. Zimmer Biomet has a 52-week low of $79.12 and a 52-week high of $108.29. The company has a market cap of $18.69 billion, a price-to-earnings ratio of 25.11, a PEG ratio of 2.82 and a beta of 0.45.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. The company had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The business’s quarterly revenue was up 4.8% on a year-over-year basis. During the same period last year, the business earned $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, sell-side analysts expect that Zimmer Biomet will post 8.48 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Thursday, June 25th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet’s payout ratio is currently 24.94%.

Insider Activity

In other news, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the transaction, the insider directly owned 27,251 shares in the company, valued at approximately $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.28% of the company’s stock.

Trending Headlines about Zimmer Biomet

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Zimmer Biomet exceeded second-quarter expectations, reporting adjusted EPS of $2.07 versus the $2.01 consensus and revenue of $2.177 billion versus estimates of $2.13 billion. Sales increased 4.8% year over year, while adjusted EPS was stable compared with the prior-year quarter. Zimmer Biomet Announces Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised or updated its full-year 2026 outlook, calling for adjusted EPS of $8.47–$8.59 and revenue of approximately $8.6 billion, above the prior revenue consensus of roughly $8.5 billion. Zimmer Biomet raises guidance on Q2 beats
• Positive Sentiment: Management commentary highlighted continued strength in the U.S. hip business, upcoming product launches and a channel-transformation initiative that could support growth over the longer term. ZBH Q2 deep dive
• Positive Sentiment: Stifel Nicolaus raised its price target from $105 to $110 and maintained a Buy rating, indicating greater confidence in Zimmer Biomet’s earnings and growth prospects. Stifel price target update
• Neutral Sentiment: Zacks characterized ZBH as a strong value stock, which may attract valuation-focused investors, although the commentary is based primarily on style metrics rather than a new company catalyst. Why Zimmer Biomet is a Strong Value Stock
• Negative Sentiment: Adjusted margins remained under pressure, potentially limiting the benefit of the revenue beat and making investors cautious about the quality and sustainability of earnings growth. ZBH Q2 Earnings Beat and 2026 View Raised

Hedge Funds Weigh In On Zimmer Biomet

Several large investors have recently bought and sold shares of the stock. NewEdge Advisors LLC raised its stake in Zimmer Biomet by 7.3% during the 4th quarter. NewEdge Advisors LLC now owns 2,982 shares of the medical equipment provider’s stock valued at $268,000 after acquiring an additional 203 shares in the last quarter. Camelot Portfolios LLC lifted its position in Zimmer Biomet by 1.8% during the 3rd quarter. Camelot Portfolios LLC now owns 11,603 shares of the medical equipment provider’s stock worth $1,143,000 after acquiring an additional 209 shares during the last quarter. Nomura Holdings Inc. increased its holdings in Zimmer Biomet by 4.6% in the 3rd quarter. Nomura Holdings Inc. now owns 4,923 shares of the medical equipment provider’s stock valued at $485,000 after buying an additional 215 shares during the period. USS Investment Management Ltd raised its stake in Zimmer Biomet by 0.5% during the fourth quarter. USS Investment Management Ltd now owns 47,216 shares of the medical equipment provider’s stock worth $4,246,000 after acquiring an additional 224 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Zimmer Biomet by 0.6% during the third quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,607 shares of the medical equipment provider’s stock worth $4,000,000 after buying an additional 234 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.